Shilpa Company Profile
What is the competitive landscape for SHILPA
SHILPA has six approved drugs.
There are five US patents protecting SHILPA drugs. There are two tentative approvals on SHILPA drugs.
Summary for Shilpa
| US Patents: | 5 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 6 |
| Patent Litigation for Shilpa: | See patent lawsuits for Shilpa |
Drugs and US Patents for Shilpa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-002 | Dec 22, 2015 | AP | RX | Yes | Yes | 9,308,195 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-002 | Dec 22, 2015 | AP | RX | Yes | Yes | 10,842,770 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-003 | Dec 22, 2015 | AP | RX | Yes | Yes | 9,308,195 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Shilpa | PEMETREXED | pemetrexed disodium | SOLUTION;INTRAVENOUS | 215179-003 | May 22, 2023 | RX | Yes | Yes | 11,147,817 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Shilpa | CAPECITABINE | capecitabine | TABLET;ORAL | 207456-002 | Dec 12, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shilpa | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 212782-001 | Aug 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shilpa Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 102165394 | ⤷ Start Trial |
| Taiwan | 201526889 | ⤷ Start Trial |
| Mexico | 341082 | ⤷ Start Trial |
| Spain | 2736054 | ⤷ Start Trial |
| Argentina | 092759 | ⤷ Start Trial |
| China | 109745287 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shilpa Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2962690 | CR 2019 00033 | Denmark | ⤷ Start Trial | PRODUCT NAME: APREMILAST ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/981 20150116 |
| 2962690 | 132019000000096 | Italy | ⤷ Start Trial | PRODUCT NAME: APREMILAST(OTEZLA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/981, 20150116 |
| 0564409 | SPC/GB02/016 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: IMATINIB (INN I.E. NON INTELLECTUAL PROPRIETARY NAME) OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; REGISTERED: CH IKS-NR: 55807 20010621; UK SG(2001) D/292083 20011108 |
| 2962690 | 122019000070 | Germany | ⤷ Start Trial | PRODUCT NAME: APREMILAST ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/981 20150115 |
| 2962690 | C201930044 | Spain | ⤷ Start Trial | PRODUCT NAME: APREMILAST O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/14/981; DATE OF AUTHORISATION: 20150115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/981; DATE OF FIRST AUTHORISATION IN EEA: 20150115 |
| 0316704 | C300045 | Netherlands | ⤷ Start Trial | PRODUCT NAME: CAPECITABINE,DESGEWENST IN DE VORM VAN EEN SOLVAAT; NATL REGISTRATION NO/DATE: EU/1/00/163/001-002 20010202; FIRST REGISTRATION: CH 54657 19980610 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
